Key result
Anticoagulation for primary prevention of ischemic stroke in nonrheumatic atrial fibrillation yielded an incremental cost per life-year gained ranging from -£400.45 to £13,221.29 over 10 years.
Why the study?
Is anticoagulation cost-effective for the primary prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation?
Population
Patients with nonrheumatic atrial fibrillation, with particular reference to the very elderly (aged >75 years)
Design
Other
Follow-up
10 years (modeled)
Authors
Loading...
May support anticoagulation in elderly nonrheumatic AF; leaves open need for contemporary validation.
Is anticoagulation cost-effective for the primary prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation?
Anticoagulation is a cost-effective strategy for the primary prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation, especially in the elderly.
Lightowlers et al. (1998) studied Nonrheumatic atrial fibrillation. Anticoagulation was evaluated on Incremental costs per life-year gained free from stroke. Anticoagulation for primary prevention of ischemic stroke in nonrheumatic atrial fibrillation yielded an incremental cost per life-year gained ranging from -£400.45 to £13,221.29 over 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: